The disclosure that Valeant Pharmaceuticals International improperly booked $58 million in revenue came as a relief to some investors Tuesday, while others viewed the revelation as confidence shaking.
from WSJ.com: US Business http://ift.tt/24o8TEO
via IFTTT
No comments:
Post a Comment